|Frederick K. Goodwin|
April 21, 1936 |
|Occupation||Psychiatrist, Research professor|
|Spouse(s)||Rosemary Goodwin, MSW|
Frederick King Goodwin (born April 21, 1936) is an American psychiatrist and Clinical Professor of Psychiatry at the George Washington University Medical Center, where he is also director of the Center on Neuroscience, Medical Progress, and Society. He is a specialist in bipolar disorder (also known as manic-depressive illness) and recurrent depression.
Goodwin was born in Cincinnati, Ohio. He received a B.S. from Georgetown University in 1958 and his M.D. from St. Louis University in 1963, and was a psychiatric resident at the University of North Carolina in Chapel Hill. In 1965, Goodwin joined the National Institute of Mental Health (NIMH) and served as NIMH Scientific Director and Chief of Intramural Research from 1981 to 1988. He was the first to report a controlled study on the effects of lithium in bipolar disorder.
He held a Presidential appointment as head of the Alcohol, Drug Abuse, and Mental Health Administration, from which he resigned following controversy over his "Violence Initiative" and his comments about inner-city youth. However, following his resignation, he was appointed by President Bush to head of NIMH, from 1992 until resigning in 1994.
He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the ACNP. He is a founder of the journal Psychiatry Research, and on the editorial boards of a number of other journals. He was president of the Psychiatric Research Society, elected in 1998.
Goodwin is a recipient of the major research awards in his field including the Hofheimer Prize from the American Psychiatric Association, the International Anna-Monika Prize for Research in Depression, the Edward A. Strecker Award, the Nola Maddox Falcone Prize from NARSAD (now known as the Brain & Behavior Research Foundation), the McAlpin Research Award from the National Mental Health Association, the Distinguished Service Award from the National Alliance on Mental Illness, and the Research Award from the American Foundation for Suicide Prevention. He was the first recipient of the Psychiatrist of the Year from Psychiatric Times, and the Fawcett Humanitarian Award of the NDMDA (now the Depression and Bipolar Support Alliance. Goodwin was one of only five psychiatrists on the Current Contents list of the most frequently cited scientists in the world and one of 12 listed in The Best Doctors in the U.S.
Since retiring from government, Goodwin has been actively involved in educating other psychiatrists through continuing medical education (CME) programs and pharmaceutical speakers' bureaus.
Goodwin hosted the award-winning radio show The Infinite Mind. Started in 1997, the show (which at its height aired on over 300 public radio stations throughout the country), won more than 30 journalism awards over 10 years and was considered “public radio’s most honored and listened to health and science program."
An article in The New York Times (Nov. 21, 2008) said that Goodwin had hosted programs that recommended the use of drugs, without disclosing that he had received over a million dollars from their manufacturers.
Goodwin was also on the board of directors of the Center for Medicine in the Public Interest, an "industry-funded front, or "Astroturf" group, which receives a majority of its funding from drug companies." and the radio show was also directly part-funded by pharmaceutical companies which was also not disclosed.
Bill Lichtenstein, the senior executive producer of the show, said that Goodwin had not disclosed payments from pharmaceutical companies, in violation of a strict conflict of interest contract. Goodwin said that Lichtenstein was aware of his educational speaking and consulting activities for pharmaceutical companies, and that in 2005 Goodwin had switched to guest host and let Peter D. Kramer host other shows, including those discussing psychopharmacological treatment, for that reason. An assistant producer of The Infinite Mind independently supported Goodwin's claim. However, 'On The Media' later issued an apology for not contacting Lichtenstein, who reports that when he himself contacted the source she said "she had no knowledge or evidence to support Goodwin's claim...that Lichtenstein or "The Infinite Mind" was aware that Goodwin was being paid to give marketing talks on behalf of pharmaceutical companies". In addition, Lichtenstein points out that Goodwin has told the BMJ (formerly the British Medical Journal) that he didn't believe there had been a conflict of interest, and told George Washington University student newspaper that "I frankly do not see these things as a conflict of interest . . . I've always thought that if you have multiple relationships they sort of cancel each other out".
In 2008, Sen. Charles Grassley (IA-R) conducted investigations regarding possible conflicts of interest between various academic psychiatrists and pharmaceutical companies. Goodwin issued a statement that The New York Times article and the follow-up editorial were filled with misstatements of fact and false implications. Grassley said in regard to a 2008 show in which Goodwin took part: "“After listening to a recording of the show, it appeared to me that the real effect of this particular episode was to undercut any criticism that antidepressants might be linked to an increased risk of suicide."
The Infinite Mind program, which was independently produced and distributed, was slated to end its production at the end of 2008 due to a lack of funding. Nevertheless, following the controversy, NPR cancelled the broadcast of reruns of the show on its Sirius Satellite Radio channel.
With Kay Redfield Jamison, Goodwin wrote Manic-Depressive Illness, the first psychiatric text to win the "Best Medical Book" award from the Association of American Publishers and Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. In addition, Dr. Goodwin has authored over 470 academic papers.